Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in newly diagnosed Type 1 Diabetes
NCT02846545Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of golimumab in type 1 diabetes mellitus (T1D), sponsored by Janssen Pharmaceutical. Started Aug 2016; status: completed.
02
Drugs
golimumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02846545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846545.